Meloxicam Tablet
Product Images NDC 72865-138

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 72865-138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

15 mg 1000s

Meloxicam Tablets USP 15 mg oral tablets in a container label from XLCare Pharmaceuticals, Inc. The label indicates an Rx only product with 1000 tablets. It includes storage instructions, pharmacist dispensing guidance, and manufacturer details for Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc.*

FDA Label Image

15 mg 100s

Meloxicam Tablets USP 15 mg oral tablet bottle label from XLCare Pharmaceuticals, Inc. The label includes the NDC number 72865-138-01, package count of 100 tablets, storage instructions, and manufacturer details. It advises pharmacists to dispense with the Medication Guide and notes the product is prescription only.*

FDA Label Image

7.5 mg 1000s

Label for Meloxicam Tablets USP 7.5 mg oral tablets from XLCare Pharmaceuticals, Inc. The label indicates a 1000 tablet count with storage instructions, dispensing guidance, and manufacturer information for Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc.*

FDA Label Image

7.5 mg 100s

Label for Meloxicam Tablets USP 7.5 mg oral tablets by XLCare Pharmaceuticals, Inc. The label indicates 100 tablets per container, prescription use only, with storage instructions between 20° to 25°C. The label also includes manufacturer and distributor information, a barcode, and a pharmacist dispensing guide note.*

FDA Label Image

Adverse Reactions

Table listing adverse effects of Meloxicam by body system, including symptoms related to cardiovascular, nervous, gastrointestinal, hematologic, liver, respiratory, skin, and urinary systems among others.*

FDA Label Image

Struct

Chemical structure of the active ingredient Meloxicam, showing its molecular composition including rings, sulfur, nitrogen, oxygen, and methyl groups.*

FDA Label Image

Table 1a

A data table titled 'Table 1a Adverse Events (%) Occurring In ≥2% of Meloxicam Patients In a 12-Week Osteoarthritis Placebo- and Active-Controlled Trial.' It compares the percentage of patients experiencing various adverse events across four groups: Placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily. The adverse events are grouped by system (Gastrointestinal, Body as a Whole, Central and Peripheral Nervous System, Respiratory, and Skin) with specific conditions listed alongside corresponding percentages of patients affected in each treatment group.*

FDA Label Image

Table 1b

A data table showing adverse events occurring in 2% or more of Meloxicam patients during 12-week rheumatoid arthritis placebo-controlled trials. It compares the incidence percentages of various disorders among patients receiving placebo, Meloxicam 7.5 mg daily, and Meloxicam 15 mg daily, categorized by gastrointestinal disorders, general disorders, infections, musculoskeletal disorders, nervous system disorders, and skin conditions.*

FDA Label Image

Table 2

Table showing adverse events occurring in 2% or more of Meloxicam patients in 4-6 weeks and 6-month active-controlled osteoarthritis trials. It compares Meloxicam 7.5 mg and 15 mg daily doses, listing adverse events by system, such as gastrointestinal, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary, with corresponding percentage incidences for each trial period.*

FDA Label Image

Table 3

A drug information panel titled "Drugs that Interfere with Hemostasis." It presents clinical impacts and interventions related to the concurrent use of Meloxicam with various drugs including anticoagulants, aspirin, ACE inhibitors, diuretics, lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed. The panel outlines risks such as bleeding, toxicity, and renal function effects, with clinical study references and recommendations for monitoring patient status during combined therapy involving Meloxicam.*

FDA Label Image

Table 4

A data table titled 'Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam.' It presents pharmacokinetic parameters including Cmax, tmax, t1/2, CL/f, and Vz/f for healthy male adults, elderly males and females (fed), and single dose in renal failure and hepatic insufficiency patients. The table compares values for 7.5 mg tablets and 15 mg capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.